ArticleJournal of cross-cultural gerontology2025
Toward Inclusive Screening of Cognitive Impairment: Validating the Visual Cognitive Assessment Test Among U.S.-Based Racially Diverse Older Adults.
Article in Journal of cross-cultural gerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Black/African American and Latino populations are disproportionately affected by Alzheimer's disease (AD), yet underrepresented in research due to biases in cognitive assessments like the Montreal Cognitive Assessment (MoCA). The Visual-based Cognitive Assessment Test (VCAT) minimizes these biases through a culturally neutral, visual-based approach. This study evaluates VCAT's comparability to MoCA and its association with plasma p-tau217, a validated AD biomarker. Cross-sectional study assessing cognitive performance in two cohorts, with plasma p-tau217 levels available in Cohort 2 only. Memory disorders clinic. Fifty-six ethnoracially diverse individuals diagnosed with normal cognition (NC), mild cognitive impairment (MCI), or dementia. Cognitive performance was assessed using VCAT and MoCA. Linear regression models analyzed differences in cognitive scores across diagnostic groups and associations with p-tau217 levels. VCAT scores were comparable to MoCA across diagnostic groups. In Cohort 1, NC had higher VCAT (β = 23.22, p < 0.001) and MoCA scores (β = 25.56, p < 0.001), while dementia had lower VCAT (β = -10.86, p < 0.001) and MoCA scores (β = -10.37, p < 0.001). Similar patterns were observed in Cohort 2. Plasma p-tau217 inversely correlated with both VCAT (β = -13.63, p < 0.001) and MoCA (β = -16.26, p < 0.001) in dementia, with no significant differences in MCI. VCAT strongly aligns with MoCA, providing a culturally unbiased alternative for cognitive screening. Its association with plasma p-tau217 highlights its potential to reflect AD pathology, supporting its clinical and research applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.